Analysts See $-0.71 EPS for Loxo Oncology, Inc. (LOXO)

September 30, 2018 - By Margaret Guttierez

Loxo Oncology, Inc. (NASDAQ:LOXO) LogoInvestors sentiment increased to 1.74 in 2018 Q2. Its up 0.58, from 1.16 in 2018Q1. It is positive, as 8 investors sold Loxo Oncology, Inc. shares while 57 reduced holdings. 58 funds opened positions while 55 raised stakes. 28.62 million shares or 4.87% less from 30.09 million shares in 2018Q1 were reported.
Opus Point Prtnrs Mgmt Ltd invested in 2.6% or 6,900 shares. One Trading L P invested in 0% or 108 shares. Moreover, Mutual Of America Mgmt Limited Liability has 0.06% invested in Loxo Oncology, Inc. (NASDAQ:LOXO). Fmr Ltd Llc invested in 2.30 million shares or 0.05% of the stock. Alliancebernstein Limited Partnership accumulated 0.06% or 477,801 shares. Financial Bank Of Montreal Can has 8,156 shares. Glenmede Tru Na stated it has 990 shares. Amundi Pioneer Asset Mngmt stated it has 74,112 shares. Lazard Asset Mngmt Limited Liability Com stated it has 0% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO). Stevens Cap Mngmt Lp reported 0.02% in Loxo Oncology, Inc. (NASDAQ:LOXO). Strs Ohio invested in 10,100 shares. Impact Limited Com holds 0.78% or 12,412 shares in its portfolio. Franklin invested in 0.03% or 285,987 shares. Panagora Asset Mngmt has invested 0.01% in Loxo Oncology, Inc. (NASDAQ:LOXO). Northern Corporation owns 327,306 shares for 0.01% of their portfolio.

Since April 20, 2018, it had 0 insider buys, and 24 selling transactions for $300.37 million activity. Shares for $423,515 were sold by Van Naarden Jacob on Monday, May 14. Shares for $8.68M were sold by Flaherty Keith T. on Thursday, June 7. 1,500 shares were sold by Burstein Jennifer, worth $280,870. $1.80M worth of Loxo Oncology, Inc. (NASDAQ:LOXO) was sold by MAYLEBEN TIMOTHY M. Another trade for 5,000 shares valued at $663,378 was made by Kunkel Lori Anne on Friday, April 20. On Friday, June 8 Fuhrman Alan sold $467,437 worth of Loxo Oncology, Inc. (NASDAQ:LOXO) or 2,625 shares.

Analysts expect Loxo Oncology, Inc. (NASDAQ:LOXO) to report $-0.71 EPS on November, 1.They anticipate $0.41 EPS change or 36.61 % from last quarter’s $-1.12 EPS. After having $-0.39 EPS previously, Loxo Oncology, Inc.’s analysts see 82.05 % EPS growth. The stock decreased 2.03% or $3.54 during the last trading session, reaching $170.83. About 243,219 shares traded. Loxo Oncology, Inc. (NASDAQ:LOXO) has risen 119.31% since September 30, 2017 and is uptrending. It has outperformed by 103.69% the S&P500.

Loxo Oncology, Inc. (NASDAQ:LOXO) Ratings Coverage

Among 9 analysts covering Loxo Oncology (NASDAQ:LOXO), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Loxo Oncology had 12 analyst reports since April 16, 2018 according to SRatingsIntel. The stock of Loxo Oncology, Inc. (NASDAQ:LOXO) earned “Overweight” rating by Morgan Stanley on Monday, April 16. Morgan Stanley maintained the shares of LOXO in report on Monday, June 4 with “Overweight” rating. The stock of Loxo Oncology, Inc. (NASDAQ:LOXO) earned “Market Perform” rating by IFS Securities on Tuesday, June 5. Stifel Nicolaus maintained Loxo Oncology, Inc. (NASDAQ:LOXO) on Wednesday, May 9 with “Buy” rating. Stifel Nicolaus maintained Loxo Oncology, Inc. (NASDAQ:LOXO) on Monday, June 4 with “Buy” rating. The firm earned “Buy” rating on Wednesday, May 30 by Piper Jaffray. The firm earned “Buy” rating on Thursday, May 17 by Stifel Nicolaus. The stock of Loxo Oncology, Inc. (NASDAQ:LOXO) earned “Market Outperform” rating by JMP Securities on Monday, June 4.

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. The company has market cap of $5.21 billion. The Company’s lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase , which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. It currently has negative earnings. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains.

More notable recent Loxo Oncology, Inc. (NASDAQ:LOXO) news were published by: which released: “Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from US Food and Drug Administration for …” on September 05, 2018, also with their article: “Key events next week – healthcare” published on September 28, 2018, published: “3 Biotech Stocks That Could Soar in September” on September 02, 2018. More interesting news about Loxo Oncology, Inc. (NASDAQ:LOXO) were released by: and their article: “Your Cancer Highlight: Loxo Breaks Through Again, Now With Its Own Drug” published on September 07, 2018 as well as‘s news article titled: “Best ETFs for 2018: Don’t Sweat This Quarter for the SBIO ETF” with publication date: September 28, 2018.

Loxo Oncology, Inc. (NASDAQ:LOXO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: